Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does 177Lu-labeled octreotate improve the rate of remission of endocrine gastroenteropancreatic tumors?

Nature Clinical Practice Endocrinology & Metabolism volume 1, pages 20–21 (2005)Cite this article

boxed-textKwekkeboom DJ et al. (2005) Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 23: 2754–2762

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Otte A et al. (1997) DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 24: 792–795

    CAS  PubMed  Google Scholar 

  2. Eberle AN et al. (2004) Receptor-mediated tumor targeting with radiopeptides. Part 1. General concepts and methods: applications to somatostatin receptor-expressing tumors. J Recept Signal Transduct 24: 319–455

    Article  CAS  Google Scholar 

  3. Jamar F et al. (2003) 86Y-DOTA-d-Phe1-Tyr3-octreotide (SMT487)—a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 30: 510–518

    Article  CAS  Google Scholar 

  4. Paganelli G et al. (2002) 90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies. Biopolymers 66: 393–398

    Article  CAS  Google Scholar 

  5. De Jong et al. (2005) Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med 46 (Suppl 1): 13S–17S

    Google Scholar 

Download references

Acknowledgements

The synopsis was written by Ian Newman, Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Professor of Pathobiology and Clinical Research, and C Beglinger is a Professor of Gastroenterology, the University Hospital Basel, Switzerland

    Alex N Eberle & Christoph Beglinger

Authors
  1. Alex N Eberle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christoph Beglinger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alex N Eberle.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eberle, A., Beglinger, C. Does 177Lu-labeled octreotate improve the rate of remission of endocrine gastroenteropancreatic tumors?. Nat Rev Endocrinol 1, 20–21 (2005). https://doi.org/10.1038/ncpendmet0028

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0028

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing